Multidrug resistance reversal agent, NSC77037, Identified with a cell-based screening assay

Michiro Susa, Edwin Choy, C. A O Yang, Joseph Schwab, Henry Mankin, Francis Hornicek, Zhenfeng Duan

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

The development of multidrug resistance (MDR) remains a significant obstacle in treating cancer patients with chemotherapy. To identify small-molecule compounds that can reverse MDR, the authors used a cell-based screening assay with an MDR ovarian cancer cell line. Incubating MDR cells with a sublethal concentration of paclitaxel in combination with each of 2000 small-molecule compounds from the National Cancer Institute Diversity Set Library, they identified NSC77037. The cytotoxic activity of NSC77037 and the duration of its effect were evaluated in vitro using a panel of cancer cell lines expressing permeability glycoprotein (Pgp), multiple drug resistance protein 1 (MRP 1 ), and breast cancer resistance protein (BCRP). The mechanism of its effects was further analyzed by assessing the retention of calcein and. Pgp-ATPase activity. The relative potency of MDR reversal by NSC77037 was significantly higher than that of frequently used. MDR reversal agents such as verapamil and cyclosporine A. NSC77037 reversed Pgp without reversing MRP or BCRP-mediated MDR. NSC77037, at a concentration of >10 μM, moderately inhibited the proliferation of both sensitive and resistant cell lines, but the inhibitory effect of NSC77037 was not altered by coincubation with the Pgp inhibitor verapamil, suggesting that NSC77037 itself is not a substrate of Pgp. NSC77037 directly inhibited the function of Pgp in a dose-dependent manner, but it did not alter the protein expression level of Pgp. The use of NSC77037 to restore sensitivity to chemotherapy or to prevent resistance could be a potential treatment strategy for cancer patients.

Original languageEnglish
Pages (from-to)287-296
Number of pages10
JournalJournal of Biomolecular Screening
Volume15
Issue number3
DOIs
Publication statusPublished - 2010
Externally publishedYes

Fingerprint

tetrandrine
Multiple Drug Resistance
Assays
Glycoproteins
Screening
Permeability
Chemotherapy
Cells
P-Glycoproteins
Verapamil
BRCA1 Protein
Cell Line
Proteins
Molecules
Paclitaxel
Drug Therapy
Neoplasms
Cyclosporine
National Cancer Institute (U.S.)
Adenosine Triphosphatases

Keywords

  • Cell-based screening
  • Drug resistance
  • Nsc77037/tetrandrine
  • Pgp

ASJC Scopus subject areas

  • Analytical Chemistry
  • Drug Discovery
  • Pharmacology
  • Biochemistry
  • Molecular Medicine
  • Biotechnology

Cite this

Susa, M., Choy, E., Yang, C. A. O., Schwab, J., Mankin, H., Hornicek, F., & Duan, Z. (2010). Multidrug resistance reversal agent, NSC77037, Identified with a cell-based screening assay. Journal of Biomolecular Screening, 15(3), 287-296. https://doi.org/10.1177/1087057109359422

Multidrug resistance reversal agent, NSC77037, Identified with a cell-based screening assay. / Susa, Michiro; Choy, Edwin; Yang, C. A O; Schwab, Joseph; Mankin, Henry; Hornicek, Francis; Duan, Zhenfeng.

In: Journal of Biomolecular Screening, Vol. 15, No. 3, 2010, p. 287-296.

Research output: Contribution to journalArticle

Susa, M, Choy, E, Yang, CAO, Schwab, J, Mankin, H, Hornicek, F & Duan, Z 2010, 'Multidrug resistance reversal agent, NSC77037, Identified with a cell-based screening assay', Journal of Biomolecular Screening, vol. 15, no. 3, pp. 287-296. https://doi.org/10.1177/1087057109359422
Susa, Michiro ; Choy, Edwin ; Yang, C. A O ; Schwab, Joseph ; Mankin, Henry ; Hornicek, Francis ; Duan, Zhenfeng. / Multidrug resistance reversal agent, NSC77037, Identified with a cell-based screening assay. In: Journal of Biomolecular Screening. 2010 ; Vol. 15, No. 3. pp. 287-296.
@article{d50f1551b6dd474daee13d33f355e883,
title = "Multidrug resistance reversal agent, NSC77037, Identified with a cell-based screening assay",
abstract = "The development of multidrug resistance (MDR) remains a significant obstacle in treating cancer patients with chemotherapy. To identify small-molecule compounds that can reverse MDR, the authors used a cell-based screening assay with an MDR ovarian cancer cell line. Incubating MDR cells with a sublethal concentration of paclitaxel in combination with each of 2000 small-molecule compounds from the National Cancer Institute Diversity Set Library, they identified NSC77037. The cytotoxic activity of NSC77037 and the duration of its effect were evaluated in vitro using a panel of cancer cell lines expressing permeability glycoprotein (Pgp), multiple drug resistance protein 1 (MRP 1 ), and breast cancer resistance protein (BCRP). The mechanism of its effects was further analyzed by assessing the retention of calcein and. Pgp-ATPase activity. The relative potency of MDR reversal by NSC77037 was significantly higher than that of frequently used. MDR reversal agents such as verapamil and cyclosporine A. NSC77037 reversed Pgp without reversing MRP or BCRP-mediated MDR. NSC77037, at a concentration of >10 μM, moderately inhibited the proliferation of both sensitive and resistant cell lines, but the inhibitory effect of NSC77037 was not altered by coincubation with the Pgp inhibitor verapamil, suggesting that NSC77037 itself is not a substrate of Pgp. NSC77037 directly inhibited the function of Pgp in a dose-dependent manner, but it did not alter the protein expression level of Pgp. The use of NSC77037 to restore sensitivity to chemotherapy or to prevent resistance could be a potential treatment strategy for cancer patients.",
keywords = "Cell-based screening, Drug resistance, Nsc77037/tetrandrine, Pgp",
author = "Michiro Susa and Edwin Choy and Yang, {C. A O} and Joseph Schwab and Henry Mankin and Francis Hornicek and Zhenfeng Duan",
year = "2010",
doi = "10.1177/1087057109359422",
language = "English",
volume = "15",
pages = "287--296",
journal = "Journal of Biomolecular Screening",
issn = "1087-0571",
publisher = "SAGE Publications Inc.",
number = "3",

}

TY - JOUR

T1 - Multidrug resistance reversal agent, NSC77037, Identified with a cell-based screening assay

AU - Susa, Michiro

AU - Choy, Edwin

AU - Yang, C. A O

AU - Schwab, Joseph

AU - Mankin, Henry

AU - Hornicek, Francis

AU - Duan, Zhenfeng

PY - 2010

Y1 - 2010

N2 - The development of multidrug resistance (MDR) remains a significant obstacle in treating cancer patients with chemotherapy. To identify small-molecule compounds that can reverse MDR, the authors used a cell-based screening assay with an MDR ovarian cancer cell line. Incubating MDR cells with a sublethal concentration of paclitaxel in combination with each of 2000 small-molecule compounds from the National Cancer Institute Diversity Set Library, they identified NSC77037. The cytotoxic activity of NSC77037 and the duration of its effect were evaluated in vitro using a panel of cancer cell lines expressing permeability glycoprotein (Pgp), multiple drug resistance protein 1 (MRP 1 ), and breast cancer resistance protein (BCRP). The mechanism of its effects was further analyzed by assessing the retention of calcein and. Pgp-ATPase activity. The relative potency of MDR reversal by NSC77037 was significantly higher than that of frequently used. MDR reversal agents such as verapamil and cyclosporine A. NSC77037 reversed Pgp without reversing MRP or BCRP-mediated MDR. NSC77037, at a concentration of >10 μM, moderately inhibited the proliferation of both sensitive and resistant cell lines, but the inhibitory effect of NSC77037 was not altered by coincubation with the Pgp inhibitor verapamil, suggesting that NSC77037 itself is not a substrate of Pgp. NSC77037 directly inhibited the function of Pgp in a dose-dependent manner, but it did not alter the protein expression level of Pgp. The use of NSC77037 to restore sensitivity to chemotherapy or to prevent resistance could be a potential treatment strategy for cancer patients.

AB - The development of multidrug resistance (MDR) remains a significant obstacle in treating cancer patients with chemotherapy. To identify small-molecule compounds that can reverse MDR, the authors used a cell-based screening assay with an MDR ovarian cancer cell line. Incubating MDR cells with a sublethal concentration of paclitaxel in combination with each of 2000 small-molecule compounds from the National Cancer Institute Diversity Set Library, they identified NSC77037. The cytotoxic activity of NSC77037 and the duration of its effect were evaluated in vitro using a panel of cancer cell lines expressing permeability glycoprotein (Pgp), multiple drug resistance protein 1 (MRP 1 ), and breast cancer resistance protein (BCRP). The mechanism of its effects was further analyzed by assessing the retention of calcein and. Pgp-ATPase activity. The relative potency of MDR reversal by NSC77037 was significantly higher than that of frequently used. MDR reversal agents such as verapamil and cyclosporine A. NSC77037 reversed Pgp without reversing MRP or BCRP-mediated MDR. NSC77037, at a concentration of >10 μM, moderately inhibited the proliferation of both sensitive and resistant cell lines, but the inhibitory effect of NSC77037 was not altered by coincubation with the Pgp inhibitor verapamil, suggesting that NSC77037 itself is not a substrate of Pgp. NSC77037 directly inhibited the function of Pgp in a dose-dependent manner, but it did not alter the protein expression level of Pgp. The use of NSC77037 to restore sensitivity to chemotherapy or to prevent resistance could be a potential treatment strategy for cancer patients.

KW - Cell-based screening

KW - Drug resistance

KW - Nsc77037/tetrandrine

KW - Pgp

UR - http://www.scopus.com/inward/record.url?scp=77949342231&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949342231&partnerID=8YFLogxK

U2 - 10.1177/1087057109359422

DO - 10.1177/1087057109359422

M3 - Article

C2 - 20150589

AN - SCOPUS:77949342231

VL - 15

SP - 287

EP - 296

JO - Journal of Biomolecular Screening

JF - Journal of Biomolecular Screening

SN - 1087-0571

IS - 3

ER -